A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies

Protocol No

SCHRODINGER-SGR-1505-101

Phase

I

Summary

This project is being done to learn about the effects of a new drug, SGR-1505, to find the best dose for treating B-cell cancers, and to see how safe and tolerable SGR-1505 is for patients with the same or similar blood cancers as yours.

Description

A Phase 1 Study if SGR-1505 in Patients with B-Cell Malignancies

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL